Roche/Hitachi Clinical Analyzer Financing:
cobas c 503, c 702 & e 801 Modules.

iLease Capital finances Roche cobas clinical analyzer systems when the instrument is genuinely owned and transferable. Call (866) 545-3273 with the exact platform, module list, serial numbers, seller quote and, most important, the reagent-contract status before you commit. iLease Capital is an equipment-finance company with a network of more than 50 lenders and can structure eligible transactions up to $5 million plus.

Roche cobas analyzers are different from most lab equipment in one way that changes the entire financing conversation. Across clinical chemistry and immunoassay, the large majority of cobas systems in the field are not owned by the lab that runs them. They are placed under reagent-rental or cost-per-test agreements, where Roche provides the instrument at little or no upfront cost against a commitment to buy reagents, and the analyzer returns to Roche at the end of the contract. An instrument on a placement agreement is not the lab's asset to sell or pledge, which means it usually cannot be financed as collateral. This page is honest about that, and it focuses on the specific situations where an outright purchase, and financing, actually make sense.

Start your application at ileasecapital.com/apply. It takes about three minutes and there is no hard credit pull.

Platforms Covered

This page focuses on cobas c 503, c 702 and e 801 chemistry and immunoassay modules and the cobas 8000 and cobas pro platforms they run on. In reference labs and hospital central laboratories these are configured as modular high-throughput lines with sample handling, clinical chemistry and immunoassay modules. Hitachi High-Tech has a long manufacturing relationship behind portions of Roche's clinical chemistry platform, which is why both names appear in the product history and on the used market.

The c 503 is a clinical chemistry module, the c 702 a high-throughput chemistry module and the e 801 an immunoassay module. They have different functions and different values, so the financing file should identify every module by serial number rather than describing the system in general terms.

The Reagent-Rental Reality

The reason cobas financing is not routine is the placement model. Under a reagent agreement, the instrument is effectively bundled into the reagent price. The lab does not hold title, cannot freely resell the unit, and is typically obligated to return it. From a lender's point of view there is no collateral to advance against, because the borrower does not own the thing being financed.

That is why the first question on any cobas deal is not price or condition. It is ownership. Before financing can be structured, the buyer has to establish that the specific unit is sold outright with clear title, is free of any return-to-manufacturer obligation, and that any transferable software, licenses and service coverage actually move with the asset. Where those facts are confirmed, a cobas system can be financed like other lab equipment. Where they are not, no amount of price negotiation changes the fact that the instrument cannot serve as collateral.

Because so many units never sell outright, resale evidence is thin and heavily configuration-dependent. That thinness is itself a financing factor, and it is a reason to document the specific system carefully.

When Outright Purchase and Financing Make Sense

There are real situations where buying a cobas system outright, and financing it, is the right move rather than staying on a placement. The common ones:

High-volume labs escaping cost-per-test economics. At sustained high test volumes, the per-test reagent premium built into a placement can exceed the cost of owning the analyzer. A lab that has the volume to justify ownership can buy the instrument outright, finance the capital cost over its useful life, and buy reagents at list rather than at placement pricing. This is the strongest ownership case.

Refurbished units sold free and clear. Independent dealers sell refurbished cobas modules and complete systems that are not tied to a Roche contract. When the seller can document clear title and transferability, the unit is genuine ownable collateral and finances like other refurbished lab equipment.

End-of-placement buyout. A lab already running a placed instrument sometimes has the option to purchase it at contract end. Financing that buyout can be sensible when the instrument still has useful life and the purchase price reflects a used, not new, valuation.

Non-clinical and secondary-site use. Veterinary, research, toxicology and other non-clinical labs, and satellite or backup sites, often run cobas chemistry outside a standard Roche placement. In those settings an outright purchase is frequently the only path, and financing spreads the cost.

Vendor consolidation or avoiding volume commitments. A lab that does not want to commit to placement minimums, or that is consolidating vendors, may prefer to own its analyzers outright. Financing makes that possible without a large single capital outlay.

In each of these, the deal works because the instrument is genuinely the lab's asset. Call (866) 545-3273 and we will tell you quickly whether a specific unit fits one of these ownership cases.

Current Used Market Pricing

Because these analyzers are usually placed under reagent agreements rather than sold outright, resale evidence is thin and prices are contract-sensitive. Where units do appear on the secondary market, recent listings as of September 2026 show a refurbished c 503 asking around $18,800 and a complete cobas 8000 with an e 801 module listed around $30,000; c 702 and related modules run roughly $30,000 to $90,000 depending on refurbishment and completeness. Reagent-placement and outright-sale pricing must not be mixed, and complete new installations are quote-only.

These are published asking prices, not completed-sale values or appraisals. Freight, installation, warranty, refurbishment and configuration can move the transaction materially. Asking prices shift with market conditions, call us at (866) 545-3273 for current pricing on a specific system.

Establishing That the Instrument Is Yours to Finance

This is the step that determines whether a cobas deal can happen at all. Confirm that the sale is an outright transfer with clear title, not a reassignment of a placement. Get written confirmation from the seller, and where appropriate from Roche or the authorized service organization, that the unit carries no return obligation and no active reagent-rental encumbrance. Confirm that software licenses, activation keys and any service coverage are transferable to the buyer. Resolve any liens rather than assuming a bill of sale is sufficient.

If those facts cannot be established, the honest answer is that the instrument is not financeable as collateral, and we will tell you that rather than structuring a deal that cannot close.

What Lenders Evaluate

For a cobas system that is confirmed ownable, configuration is the asset. The file should identify the core platform, each analytical module, the sample-handling and core units, workstation and software, and support equipment such as water systems and interfaces. Software licenses and any service agreements should be verified for transferability.

A system that powers on is not necessarily analytically ready. Ask for recent qualification, calibration or performance data. Confirm the deinstallation method and whether a qualified engineer will reinstall the system. Clinical analyzers lose value quickly when critical modules, software keys or accessories are separated from the platform, so a complete, supportable system finances more easily than a cheaper incomplete one.

New Versus Used or Refurbished

New equipment provides a clean invoice and known configuration, though new cobas lines are quote-only and normally acquired through Roche. Used and refurbished equipment can be financed when identity, condition, transferability and market support are clear.

Refurbished should mean more than cleaning. Ask what was tested, replaced, calibrated or rebuilt, and request the refurbishment checklist and warranty. A dealer premium can be reasonable when it buys meaningful inspection, warranty, installation, service, and documented clear title.

Dealer Versus Private-Party Purchase

Dealer purchases usually provide stronger documentation and may include installation, warranty and, critically, a clear statement of title and transferability. Private-party purchases can offer value but require clear ownership and a detailed equipment description.

Confirm serial numbers, seller identity and ownership before closing. On cobas specifically, confirm the unit is not being sold out from under an active placement.

Service Contracts and Support

Service can be central to uptime but it is not automatically transferable. Ask the manufacturer or authorized service organization whether coverage follows the asset, requires recertification, or terminates at sale. Budget for a new contract where transfer is uncertain. Parts availability and local technical support also affect practical resale even between otherwise similar systems.

Software, Electronics and Licenses

Modern analyzers combine durable hardware with licensed software. Verify which licenses are perpetual and transferable versus tied to the original owner, and confirm workstation specifications and whether activation keys are included. Confirm acquisition and results software separately, since a system missing its licensed software is worth far less as collateral.

Installation and Site Requirements

Delivered price is not the same as installed cost. Cobas lines can require water systems, drainage, uninterruptible power, benching, interfaces to the laboratory information system, and environmental control. Identify these costs before closing so the acquisition budget reflects the system entering service rather than merely arriving.

What to Have Ready

Prepare the manufacturer, exact platform, module list with serial numbers, year, purchase price, seller and location, plus the reagent-contract and title status. Add photographs, instrument-status records, service history and a complete module and software list. Separate freight, rigging, installation and training charges when possible so the core analyzer collateral is clear.

Inspection Before Purchase

Inspect the expensive failure points rather than relying on cosmetic condition. Request power-on status and recent service and performance records. Inspect pumps, sample-handling mechanisms, detectors, reagent-handling systems and the workstation. Confirm that proprietary accessories and modules are present. A third-party inspection can be worthwhile when the system is remote or high value.

Monthly Payment and Structure

Monthly payment depends on the system, amount, term, borrower profile and structure. iLease Capital does not use one universal rate for every asset. Choose the configuration based on operating fit first, then evaluate the payment for that actual configuration. Call (866) 545-3273 with the seller quote and confirmed title status. Eligible transactions can be structured up to $5 million plus through iLease Capital's lender network.

Start your application at ileasecapital.com/apply. It takes about three minutes and there is no hard credit pull.

Collateral Value Versus Purchase Price

Purchase price and collateral value are related but not identical. Warranty, installation, software, training and refurbishment can increase acquisition cost without adding dollar-for-dollar liquidation value, so document those items rather than hiding them inside one number. If the price is above comparable listings, explain why. If it is unusually low, determine whether missing modules, condition, or an active placement obligation explains the discount.

Documentation That Supports Value

Keep service reports, calibration or qualification records, repair invoices and module lists. Photograph serial plates and capture instrument-status screens. Retain dated invoices for any major component replacement. Complete records support both the financing review and eventual resale, and they help demonstrate the clear title that a cobas deal depends on.

Logistics and Delivery

Clinical analyzers may require specialized deinstallation, crating, air-ride freight and manufacturer or third-party reinstallation. Heavy modules can also need rigging. Get logistics quotes early when the cost is material, and confirm who is responsible for a compliant reinstall.

Market Liquidity

Secondary-market depth matters because a specialized analyzer needs another qualified buyer when it is eventually sold. Recognizable platforms can have demand, but configuration and clear title control liquidity. A complete, documented, ownable system finds a buyer far more readily than an incomplete unit or one whose ownership history is unclear.

Why iLease Capital

iLease Capital finances equipment for a living and we are direct about where cobas systems fit. We will tell you when an instrument is a clean ownable purchase we can finance, and we will tell you when it is a placement that cannot serve as collateral, rather than pushing a deal that will not close. We work with a network of more than 50 lenders and match each eligible deal to the right funding partner. Call (866) 545-3273 and talk to a specialist, not a call center.

Frequently asked questions